top of page
bannerimg.jpg

Mission Statement

Thrombotic Microangiopathy

The mission of the USTMA is to improve outcomes in thrombotic microangiopathies (TMA) through collaboration and advocacy

paient_home.png
ABOUT US

Thrombotic Microangiopathy represents a broad range of diseases

The term thrombotic microangiopathy or TMA represents a broad pathophysiologic process that leads to the development of a microangiopathic hemolytic anemia (MAHA)

  • RESEARCH FACILITIES AND RESOURCES

The MAHA is a result of a micro thrombotic disease that involves the arterioles and capillaries of vascular beds throughout the body. These widespread microthrombi are the cause of the widespread and varied end organ injury that can be seen in patients diagnosed with a TMA. The term TMA is also an umbrella term that encompasses many conditions that can present with the characteristic MAHA and thrombocytopenia, but with differing and distinct pathophysiologies and treatment approaches.

man-woman-woman-experiment.jpg
bannerimg.jpg

Subscribe to our newsletter • Don’t miss out!

Thanks for subscribing!

OUR BOARD FOR THE CONSORTIUM

Led by Passionate Experts

team-img01.jpg

Marshall Mazepa, MD

University of Minnesota

team-img02.jpg

Spero R Cataland, MD

Ohio State University

team-img04.jpg

Ara Metjian, MD

University of Colorado

shruti.jpg

Shruti Chaturvedi, M.B.B.S., MS

Johns Hopkins University

Satheesh-Chonat.jpg

Satheesh Chonat, MD

Children's Healthcare of Atlanta

Contact

Contact Us

Thanks for submitting!

bottom of page